DGX — Quest Diagnostics Incorporated stock price, charts and financials

QT70Quest Diagnostics Incorporated

Quest Diagnostics Incorporated (NYSE: DGX) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
231.95
-1.06-0.45%
DGXQT70Quest Diagnostics Incorporated·NYSE
231.95-0.45%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E24.42EPS (ttm)9.54Insider Own1.06%Shs Outstand110.37MPerf Week2.26%
Market Cap25.72BForward P/E19.36EPS next Y12.03Insider Trans-6.95%Shs Float109.84MPerf Month7.87%
Enterprise Value31.48BPEG1.93EPS next Q2.80Inst Own-Short Float3.20%Perf Quarter19.98%
Income1.06BP/S2.22EPS this Y18.59%Inst Trans-Short Ratio3.83Perf Half Y27.78%
Sales11.56BP/B3.41EPS next Y7.72%ROA6.27%Short Interest3.51MPerf YTD34.28%
Book/sh-P/C14.45EPS next 5Y7.32%ROE14.49%52W High239.05 -2.97%Perf Year38.10%
Cash/sh-P/FCF21.08EPS past 3/5Y3.12% -3.62%ROIC8.25%52W Low166.00 39.73%Perf 3Y71.03%
Dividend Est.3.44 (1.48%)EV/EBITDA15.67Sales past 3/5Y3.74% 3.18%Gross Margin33.15%Volatility2.39% 2.77%Perf 5Y67.12%
Dividend TTM3.32 (1.43%)EV/Sales2.72EPS Y/Y TTM22.50%Oper. Margin14.14%ATR (14)6.59Perf 10Y177.33%
Dividend Ex-DateJul 08, 2026Quick Ratio1.46Sales Y/Y TTM17.10%Profit Margin9.19%RSI (14)71.48Recom2.71
Dividend Gr. 3/5Y6.61% 7.35%Current Ratio1.59EPS Q/Q19.08%SMA207.50%Beta0.55Target Price240.25
Payout34.18%Debt/Eq0.85Sales Q/Q10.21%SMA5012.61%Rel Volume0.94Prev Close233.01
Employees57,000LT Debt/Eq0.86EarningsOct 20SMA20020.08%Avg Volume928.75KPrice231.95
IPO DateDec 17, 1996Option/ShortYes / YesEPS/Sales Surpr.10.53% 2.36%Net Debt/EBITDA2.87Volume872,394Change-0.45%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-29-26ReiteratedArgus ResearchBuy$225$260
Jul-24-26ReiteratedRobert W. Baird$236$255
Jul-24-26ReiteratedUBSNeutral$210$232
Jul-23-26ReiteratedJefferiesBuy$225$245
Jul-13-26ReiteratedRobert W. Baird$232$236
Apr-21-26ReiteratedEvercore ISIIn Line$210$225
Apr-21-26ReiteratedJefferiesBuy$220$225
Apr-08-26ReiteratedEvercore ISI GroupIn Line$220$210
Feb-12-26ReiteratedMizuhoOutperform$210$235
Feb-11-26ReiteratedRobert W. Baird$203$219
Latest News
Today
Jul-31-26
Jul-30-26
Jul-28-26
Jul-27-26
Jul-26-26
Jul-24-26
Jul-23-26
Jul-23-2603:08PM
Company

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue11,56011,0359,8729,2529,88310,7889,4377,7267,531
Cost of Goods Sold Incl. D&A7,7287,5126,6286,1996,4506,5795,8045,0374,926
Gross Profit3,8323,5233,2443,0693,4334,2093,6332,6892,605
Selling, General and Administrative Excl. Other2,0201,9671,7701,6151,8741,7271,5501,4571,424
Research and Development
000000000
Other Operating Expense177-47128192131101112176
Operating Income1,6351,6031,3461,2621,4282,3811,9711,2311,101
Interest Expense262277226163148152166180169
Unusual Expense
Non-Operating Income (Expense)46347457-144815482-6
Net Income Before Taxes1,4191,3601,1941,1561,2792,6771,9591,133926
Income Taxes320314273248264597460247182
Consolidated Net Income1,0629928718549461,9951,431858736
Net Income From Continuing Operations1,0991,0469219081,0152,0801,499886788
Net Income1,0629928718549461,9951,431858736
EPS (Recurring)9.548.877.807.598.1215.9010.686.385.41
EPS (Basic, Before Extraordinaries)9.548.877.807.598.1215.9010.686.385.41
EPS (Diluted)9.428.757.697.527.9815.5310.526.295.29
EBITDA2,0082,1941,8941,7321,8203,1592,4111,5851,404
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio24.6219.8319.6218.3419.6011.1411.3316.9815.74
Price To Sales Ratio2.211.751.701.671.842.001.691.851.50
Gross Margin33.1531.9332.8633.1734.7439.0238.5034.8034.59
Operating Margin14.1414.5313.6313.6414.4522.0720.8915.9314.62
Net Margin9.198.998.829.239.5718.4915.1611.119.77
Shares Outstanding110111111112116125134134136
Market Capitalization25,51519,26216,74515,44318,14721,62615,96914,31011,325
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$246.37$223.77$201.18$178.59$155.99 Close Price0.00M3.08M6.16M9.24M12.32MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DELANEY MARK ESVP & Chief Commercial OfficerJul 28 '26Sale235.181,600376,28810,335Jul 29
KUPPUSAMY KARTHIKSVP, Clinical SolutionsJun 04 '26Sale200.008,1471,629,40013,510Jun 08
KUPPUSAMY KARTHIKSVP, Clinical SolutionsJun 04 '26Option Exercise124.228,1471,012,00021,657Jun 08
Davis J. E.CEO and PresidentJun 01 '26Sale194.1410,0001,941,400132,423Jun 02
Plewman PatrickSVP for Diagnostic ServicesMar 05 '26Sale206.212,855588,73015,198Mar 06
Doherty Catherine T.EVP, Regional BusinessesMar 05 '26Sale206.215,5581,146,11567,122Mar 06
PREVOZNIK MICHAEL ESVP & General CounselMar 05 '26Sale206.213,878799,68237,557Mar 06
KUPPUSAMY KARTHIKSVP, Clinical SolutionsMar 04 '26Sale204.862,628538,37213,441Mar 06
Plewman PatrickSVP for Diagnostic ServicesMar 03 '26Sale207.7341085,16915,198Mar 04
Doherty Catherine T.EVP, Regional BusinessesMar 03 '26Sale207.73632131,28567,122Mar 04
PREVOZNIK MICHAEL ESVP & General CounselMar 03 '26Sale207.73526109,26637,557Mar 04
Davis J. E.CEO and PresidentMar 02 '26Sale212.5210,0002,125,200117,185Mar 04
PREVOZNIK MICHAEL ESVP & General CounselFeb 19 '26Sale204.831,111227,56638,371Feb 20
Doherty Catherine T.EVP, Regional BusinessesFeb 19 '26Sale204.831,433293,52168,402Feb 20
Plewman PatrickSVP for Diagnostic ServicesFeb 19 '26Sale204.83958196,22715,838Feb 20
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.